Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2025

Conditions
Metabolic-associated Fatty Liver DiseaseType 2 Diabetes
Interventions
DRUG

Empagliflozin

Empagliflozin 10 mg p.o. once daily (available to control over \~25mg)

DRUG

Dulaglutide

Dulaglutide 0.75mg s.c. once a week (available to control over \~1.5mg)

DRUG

Empagliflozin and Dulaglutide

Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly

All Listed Sponsors
lead

Seoul National University Bundang Hospital

OTHER

NCT05140694 - Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D | Biotech Hunter | Biotech Hunter